The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
REJOICE-PanTumor01: A phase 2 signal-seeking study of raludotatug deruxtecan (R-DXd) in patients with advanced or metastatic gynecologic or genitourinary tumors.
 
Laurence Albiges
Consulting or Advisory Role - Astellas Pharma (Inst); Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo Europe GmbH (Inst); Eisai (Inst); Ipsen (Inst); Janssen (Inst); Merck (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); Telix Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - BMS; Ipsen; MSD; Pfizer
 
Kenichi Harano
Honoraria - AstraZeneca; Chugai Pharma; Eisai; Kyowa Kirin International; MSD K.K; Takeda
Consulting or Advisory Role - astrazeneca; Chugai Pharma; Daiichi Sankyo/UCB Japan; Taiho Pharmaceutical; Takeda
Research Funding - AstraZeneca (Inst); Chugai Pharma (Inst); Daiichi-Sankyo (Inst); Merck (Inst); Takeda (Inst)
 
Kathleen Moore
Leadership - GOG Partners; NRG Oncology (Inst)
Honoraria - Astellas Medivation; Clinical Education Alliance; Haymarket Medical Education; IDEOlogy Health; Medscape; The Clearity Foundation
Consulting or Advisory Role - AADi; Abbvie; ADC Therapeutics; AstraZeneca; BioNTech SE; Blueprint Medicines (Inst); Bristol Myers Squibb Foundation; Caris Life Sciences; Clovis Oncology; Corcept Therapeutics; Daiichi Sankyo Europe GmbH; Duality Biologics (Inst); Eisai; Elucida Oncology; Exelixis; Genentech/Roche; GlaxoSmithKline/Tesaro (Inst); immunocore; Immunogen; Iovance Biotherapeutics; Janssen Oncology; Loxo/Lilly; Merck; Mersana (Inst); Novocure; ProfoundBio; Regeneron; Roche; Sanofi/Aventis; Schrodinger (Inst); seagen; T knife; Takeda Science Foundation; Tango Therapeutics; Third Arc; Tubulis GmbH; Verastem/Pharmacyclics; Xencor; zentalis; zymeworks
Research Funding - Amgen (Inst); artios (Inst); AstraZeneca (Inst); Daiichi Sankyo/Lilly (Inst); Immunocore (Inst); Immunogen (Inst); Merck (Inst); Regeneron (Inst); Verastem (Inst)
Other Relationship - GOG Partners (Inst)
 
Thomas Powles
Honoraria - Astellas Pharma; AstraZeneca; BMS GmbH & Co. KG; Eisai; Exelixis; Incyte; Ipsen; Johnson & Johnson/Janssen; MashupMD; Merck; Merck Serono; Novartis; Pfizer; Roche; Seagen
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Eisai; Exelixis; Incyte; Ipsen; Johnson & Johnson; MashupMD; Merck; Merck Serono; MSD; Novartis; Pfizer; Roche; Seagen
Research Funding - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Eisai; Exelixis; Ipsen; Johnson & Johnson; Merck Serono; MSD; Novartis; Pfizer; Roche; Seagen
Travel, Accommodations, Expenses - AstraZeneca; Ipsen; MSD; Pfizer; Roche
 
Toon Van Gorp
Consulting or Advisory Role - Abbvie (Inst); AstraZeneca (Inst); BioNTech SE (Inst); Daiichi Sankyo (Inst); Eisai Europe (Inst); GlaxoSmithKline (Inst); Immunogen (Inst); Incyte (Inst); Karyopharm Therapeutics (Inst); MSD/Merck (Inst); OncXerna Therapeutics (Inst); Seagen (Inst); Tubulis GmbH (Inst); Zentalis (Inst)
Speakers' Bureau - Abbvie (Inst); AstraZeneca (Inst); Eisai (Inst); GlaxoSmithKline (Inst); MSD (Inst)
Research Funding - Amgen (Inst); AstraZeneca (Inst); Roche (Inst)
Travel, Accommodations, Expenses - AstraZeneca (Inst); GlaxoSmithKline (Inst); Immunogen (Inst); MSD/Merck (Inst); PharmaMar (Inst)
 
Laura Palmeri
Employment - Daiichi Sankyo Europe GmbH
 
Laura Winters
Employment - Daiichi-Sankyo
Stock and Other Ownership Interests - Daiichi-Sankyo
Travel, Accommodations, Expenses - Daiichi-Sankyo
 
Soham Mahato
Employment - Daiichi Sankyo; Novavax
Stock and Other Ownership Interests - Lilly; Novavax; Pfizer
 
Jie Lin
Employment - Daiichi Sankyo
Stock and Other Ownership Interests - Daiichi Sankyo
 
Petar Jelinic
Stock and Other Ownership Interests - Merck
 
Susana Banerjee
Stock and Other Ownership Interests - Innotive Diagnostics; Perci Health
Honoraria - Abbvie; AstraZeneca; Eisai; GlaxoSmithKline; Immunogen; MSD Oncology; Pharmaand; Verastem
Consulting or Advisory Role - Abbvie; Astrazeneca; Biogene; BioNTech SE; Eisai; Genmab; Gilead Sciences; GlaxoSmithKline; Grey Wolf Therapeutics; Immunogen; Incyte; ITM Oncologics; Lilly; MSD Oncology; Myriad Genetics; Seagen; Torl Biotherapeutics; Verastem; Zymeworks
Research Funding - AstraZeneca (Inst); GlaxoSmithKline (Inst)
Travel, Accommodations, Expenses - AstraZeneca; GlaxoSmithKline; Verastem; Zymeworks
(OPTIONAL) Uncompensated Relationships - International Cancer Foundation; Royal Society of Medicine President Oncology Session